Morningstar brands and products Company Portfolio ...

YAQ006 and YAQ007 are, respectively, the intravenous and oral formulations of L-ornithine phenylacetate (L-OPA), a potent ammonia-scavenging agent. Yaqrit is preparing to start a phase 3 trial ...

Shared data underpins key advanced trials in hepatic encephalopathy, acute-on-chronic liver failure (ACLF) and decompensated cirrhosisManagement attending conference LONDON, April 28, 2025 (GLOBE ...

A decrease in VLCFA levels in brain, the main tissue affected in X-ALD, is likely because it has been shown that phenylacetate, the initial product of 4PBA breakdown, can cross the blood–brain ...

Sandra A. Banta-Wright, MN, RNC, NNP; Robert D. Steiner, MD Neonates with profound and prolonged hyperammonemia with coma due to urea cycle defect will have had a neurological insult to the brain ...